Literature DB >> 17665231

Antifungal usage in children undergoing intensive treatment for acute myeloid leukemia: analysis of the multicenter clinical trial AML-BFM 93.

T Lehrnbecher1, J Kaiser, D Varwig, J Ritter, A H Groll, U Creutzig, T Klingebiel, D Schwabe.   

Abstract

We retrospectively analyzed the antifungal usage in children with acute myeloid leukemia (AML). Overall, 211 of 304 patients (69.4%) received a total of 389 antifungal treatment episodes. In 234 episodes, initial antifungal treatment consisted of amphotericin B [as monotherapy, n = 193; median dosage (range) of amphotericin B deoxycholate 0.6 mg/kg per day (0.02-1.5 mg/kg per day) and of liposomal amphotericin B 3.0 mg/kg per day (0.6-30 mg/kg per day)], in 149 episodes of fluconazole [as monotherapy, n = 143; 5 mg/kg per day (1-29 mg/kg per day)], in 40 of flucytosine [as monotherapy, n = 1; 150 mg/kg per day (40-370 mg/kg per day)], and in 9 of itraconazole [as monotherapy, n = 8; 6 mg/kg per day (1.6-20 mg/kg per day)]. We conclude that the majority of children with AML receives at least one episode of antifungal therapy. Inappropriate dosing and combination of antimycotics need to be addressed in future educational measures.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17665231     DOI: 10.1007/s10096-007-0362-9

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  14 in total

1.  2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.

Authors:  Walter T Hughes; Donald Armstrong; Gerald P Bodey; Eric J Bow; Arthur E Brown; Thierry Calandra; Ronald Feld; Philip A Pizzo; Kenneth V I Rolston; Jerry L Shenep; Lowell S Young
Journal:  Clin Infect Dis       Date:  2002-02-13       Impact factor: 9.079

2.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

Authors:  S Ascioglu; J H Rex; B de Pauw; J E Bennett; J Bille; F Crokaert; D W Denning; J P Donnelly; J E Edwards; Z Erjavec; D Fiere; O Lortholary; J Maertens; J F Meis; T F Patterson; J Ritter; D Selleslag; P M Shah; D A Stevens; T J Walsh
Journal:  Clin Infect Dis       Date:  2001-11-26       Impact factor: 9.079

3.  Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients.

Authors:  J R Perfect; M E Klotman; C C Gilbert; D D Crawford; G L Rosner; K A Wright; W P Peters
Journal:  J Infect Dis       Date:  1992-05       Impact factor: 5.226

4.  Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.

Authors:  Ursula Creutzig; Martin Zimmermann; Dirk Reinhardt; Michael Dworzak; Jan Stary; Thomas Lehrnbecher
Journal:  J Clin Oncol       Date:  2004-11-01       Impact factor: 44.544

5.  Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution.

Authors:  Galit P Rosen; Karin Nielsen; Sungching Glenn; Jon Abelson; Jaime Deville; Theodore B Moore
Journal:  J Pediatr Hematol Oncol       Date:  2005-03       Impact factor: 1.289

6.  Current antimicrobial usage for the management of infections in leukemic patients in Japan: results of a survey.

Authors:  Minoru Yoshida; Ryuzo Ohno
Journal:  Clin Infect Dis       Date:  2004-07-15       Impact factor: 9.079

7.  Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000.

Authors:  Theoklis E Zaoutis; Kateri Heydon; Jaclyn H Chu; Thomas J Walsh; William J Steinbach
Journal:  Pediatrics       Date:  2006-03-13       Impact factor: 7.124

8.  Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines.

Authors:  Kevin W Garey; Manjunath P Pai; Katie J Suda; Robin S Turpin; Milind D Rege; Dana E Mingo; David T Bearden
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-08       Impact factor: 2.890

9.  Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93.

Authors:  T Lehrnbecher; D Varwig; J Kaiser; D Reinhardt; T Klingebiel; U Creutzig
Journal:  Leukemia       Date:  2004-01       Impact factor: 11.528

10.  Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group.

Authors:  W Kern; G Behre; T Rudolf; A Kerkhoff; A Grote-Metke; H Eimermacher; U Kubica; B Wörmann; T Büchner; W Hiddemann
Journal:  Cancer       Date:  1998-07-15       Impact factor: 6.860

View more
  2 in total

Review 1.  Pediatric Acute Myeloid Leukemia-Past, Present, and Future.

Authors:  Dirk Reinhardt; Evangelia Antoniou; Katharina Waack
Journal:  J Clin Med       Date:  2022-01-19       Impact factor: 4.241

Review 2.  Efficacy and safety of itraconazole use in infants.

Authors:  Shuang Chen; Kai-Yi Sun; Xiao-Wei Feng; Xin Ran; Jebina Lama; Yu-Ping Ran
Journal:  World J Pediatr       Date:  2016-06-10       Impact factor: 9.186

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.